Wellington Management Group
CHRS icon

Wellington Management Group’s Coherus Oncology CHRS Stock Holding History

Wellington Management Group’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-369,702
Closed -$640K – 1932
2024
Q2 		$640K Buy
369,702
+28,500
+8% +$57.4K ﹤0.01% 1752
2024
Q1 		$815K Buy
+341,202
New +$840K ﹤0.01% 1726
2023
Q4 		– Sell
-337,748
Closed -$1.26M – 1838
2023
Q3 		$1.26M Buy
337,748
+14,209
+4% +$65.6K ﹤0.01% 1567
2023
Q2 		$1.38M Buy
323,539
+232,368
+255% +$1.37M ﹤0.01% 1552
2023
Q1 		$624K Sell
91,171
-4,724
-5% -$36.7K ﹤0.01% 1794
2022
Q4 		$759K Buy
+95,895
New +$738K ﹤0.01% 1709
2021
Q3 		– Sell
-349,305
Closed -$4.83M – 2157
2021
Q2 		$4.83M Sell
349,305
-352,567
-50% -$4.99M ﹤0.01% 1515
2021
Q1 		$10.3M Sell
701,872
-939,650
-57% -$16M ﹤0.01% 1236
2020
Q4 		$28.5M Sell
1,641,522
-17,507
-1% -$312K 0.01% 952
2020
Q3 		$30.4M Hold
1,659,029
– – 0.01% 845
2020
Q2 		$29.6M Sell
1,659,029
-655,631
-28% -$11.1M 0.01% 828
2020
Q1 		$37.5M Buy
2,314,660
+35,971
+2% +$665K 0.01% 714
2019
Q4 		$41M Sell
2,278,689
-4,289,672
-65% -$79.1M 0.01% 813
2019
Q3 		$133M Sell
6,568,361
-253,827
-4% -$5.07M 0.03% 470
2019
Q2 		$151M Sell
6,822,188
-594,691
-8% -$10.3M 0.03% 447
2019
Q1 		$101M Sell
7,416,879
-246,578
-3% -$3.29M 0.02% 547
2018
Q4 		$69.4M Sell
7,663,457
-246,490
-3% -$2.85M 0.02% 618
2018
Q3 		$131M Buy
7,909,947
+177,721
+2% +$3.15M 0.03% 498
2018
Q2 		$108M Sell
7,732,226
-54,061
-0.7% -$774K 0.02% 558
2018
Q1 		$86M Buy
7,786,287
+526,889
+7% +$5.76M 0.02% 619
2017
Q4 		$63.9M Buy
7,259,398
+976,810
+16% +$10.5M 0.01% 699
2017
Q3 		$83.9M Buy
6,282,588
+1,384,453
+28% +$18.3M 0.02% 606
2017
Q2 		$70.3M Buy
4,898,135
+3,629,656
+286% +$69.8M 0.02% 626
2017
Q1 		$26.8M Buy
1,268,479
+32,150
+3% +$791K 0.01% 931
2016
Q4 		$34.8M Sell
1,236,329
-313,904
-20% -$8.78M 0.01% 821
2016
Q3 		$41.5M Sell
1,550,233
-590,770
-28% -$16.1M 0.01% 749
2016
Q2 		$36.2M Buy
2,141,003
+1,759,336
+461% +$33M 0.01% 767
2016
Q1 		$8.1M Buy
+381,667
New +$6.25M ﹤0.01% 1216

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group's CHRS Position: Q3 2024 in Review

Wellington Management Group sold out of Coherus Oncology (CHRS) in Q3 2024, closing a stake of 369,702 shares — an estimated $640K sold.

Wellington Management Group first reported a position in CHRS in Q1 2016 and held it in 28 quarters. The position peaked at $151M in Q2 2019. 128 funds tracked by Wall St. Rank hold CHRS as of Q3 2024.

  • Wellington Management Group reported no remaining Coherus Oncology position as of Q3 2024 after selling out during the quarter.
  • Wellington Management Group sold 369,702 Coherus Oncology shares in Q3 2024, an estimated $640K.
  • Wellington Management Group first reported a position in Coherus Oncology in Q1 2016 and held it in 28 quarters.
  • Wellington Management Group's Coherus Oncology position peaked at $151M in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2024.

Based on Wellington Management Group's 13F filing for Q3 2024, filed 14 Nov 2024.